GlassScriptPhysician profile
James F Libecco
NPI 1215991393
$1,106,123.93
in general payments reported to CMS, 2019-2025
55 companies · $168K in 2025
The $168K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193K · 2020: $67K · 2021: $85K · 2022: $170K · 2023: $174K · 2024: $249K · 2025: $168K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $487K · Consulting Fee: $54K · Travel and Lodging: $24K · Food and Beverage: $18K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,840 · Honoraria: $3,495 · Education: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $486,565.75 |
| Consulting Fee | $53,819.50 |
| Travel and Lodging | $23,956.16 |
| Food and Beverage | $18,434.99 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,840.00 |
| Honoraria | $3,495.30 |
| Education | $196.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $234,634.02 | 2019-2025 | |
| Lilly USA, LLC | $177,155.92 | 2019-2025 | Ebglyss, Olumiant, Taltz |
| E.R. Squibb & Sons, L.L.C. | $119,984.92 | 2021-2025 | Sotyktu |
| Ucb, INC. | $110,405.94 | 2019-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $101,005.40 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Janssen Biotech, INC. | $88,969.75 | 2019-2025 | Tremfya |
| Janssen Scientific Affairs, LLC | $83,267.73 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $79,762.23 | 2019-2025 | |
| Incyte Corporation | $29,224.20 | 2021-2024 | Opzelura |
| Galderma Laboratories, L.P. | $26,873.04 | 2019-2025 | Nemluvio, Aklief, Dysport |
| Dermavant Sciences, INC. | $24,155.92 | 2022-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $8,202.24 | 2019-2024 | Dupixent, Libtayo |
| Genzyme Corporation | $7,946.44 | 2019-2025 | |
| Leo Pharma INC. | $5,224.46 | 2019-2025 | Adbry, Anzupgo, Spevigo |
| Organon LLC | $3,431.90 | 2024-2025 | Vtama |
Show all 54 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Libecco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.